研究実績

2020年 発表論文

研究No. 執筆者/論文タイトル/掲載誌
TORG0503 Kubota K, Kunitoh H, Seto T, et al.: Randomized phase II trial of adjuvant chemotherapy with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: TORG 0503. Lung Cancer 141: 32-36, 2020
TORG0808
TORG0913
Nakahara Y, Shimokawa T, Misumi Y, et al.: Phase I/II study of erlotinib plus S-1 for patients with previously treated non-small cell lung cancer: Thoracic Oncology Research Group (TORG) 0808/0913. Investigational New Drugs (published online 15 Aug 2020) doi: 10.1007/s10637-020-00985-4
TORG1320 Otani S, Sasaki J, Nakahara Y, et al.: Phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (TORG1320). Investigational New Drugs (published online 07 Nov 2020) doi: 10.1007/s10637-020-01031-z
TORG1322 Zenke Y, Niho S, Umemura S, et al.: Phase I/II study of carboplatin plus weekly nab-paclitaxel in patients aged ≥75 years with squamous-cell lung cancer: TORG1322. Lung Cancer 146 (8): 182-188, 2020. doi:10.1016/j.lungcan.2020.05.005
TORG1323 Kozuki T, Nogami N, Hataji O, et al.: Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ≥75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323. Translational Lung Cancer Research 9 (3) : 459-470, 2020. doi: 10.21037/tlcr.2020.03.29
TORG1425 Miyamoto S, Azuma K, Ishii H, et al.: Low-dose erlotinib treatment in elderly or frail patients with EGFR mutation-positive non-small cell lung cancer: A multicenter Phase 2 trial. JAMA Oncology 6 (7): e201250. doi: 10.1001/jamaoncol.2020.1250
TORG1834 Miura S, Yamanaka T, Kato T, et al.: Treatment Rationale and Design of a Phase III Study of Afatinib or Chemotherapy in Patients with Non-small-cell Lung Cancer Harboring Sensitizing Uncommon Epidermal Growth Factor Receptor Mutations (ACHILLES/TORG1834). Clinical Lung Cancer 21 (6): e592-e596. doi: 10.1016/j.cllc.2020.05.011
TORG1835 Ikeda S, Ogura T, Kato T, et al.: Rationale and protocol design for the TORG1835/NEXT-SHIP study: a phase II study of carboplatin, etoposide and nintedanib for unresectable limited/extensive disease small cell lung cancer with idiopathic pulmonary fibrosis. Therapeutic Advances in Medical Oncology 12: 1-6, 2020. doi: 10.1177/1758835920923431
TORG1936 Ikeda S, Kato T, Kenmotsu H, et al. A phase II study of atezolizumab for pretreated non-small cell lung cancer with idiopathic interstitial pneumonias. Journal of Thoracic Oncology 15: 1935-1942, 2020. doi: 10.1016/j.jtho.2020.08.018
Ikeda S, Kato T, Kenmotsu H, et al.: A phase II study of atezolizumab for pretreated advanced/recurrent non-small cell lung cancer with idiopathic interstitial pneumonias: rationale and design for the TORG1936/AMBITIOUS study. Therapeutic Advances in Medical Oncology 12: 1-6, 2020. doi: 10.1177/1758835920922022

2019年 発表論文

研究No. 執筆者/論文タイトル/掲載誌
TORG1017 Nakahara Y, Hosomi Y, Shibuya M, et al.: Multicenter study of zoledronic acid administration in non-small-cell lung cancer patients with bone metastasis: Thoracic Oncology Research Group (TORG) 1017. Molecular and Clinical Oncology 11: 349-353, 2019

2018年 発表論文

研究No. 執筆者/論文タイトル/掲載誌
TORG0809 Niho S, Ikeda N, Michimae H, et al.Overall Survival Results of the Feasibility Study of Adjuvant Chemotherapy With Docetaxel Plus Cisplatin Followed by Long-term Single-agent Administration of S-1 in Patients With Completely Resected Non-Small Cell Lung Cancer: Thoracic Oncology Research Group (TORG) 0809. American Journal of Clinical Oncology 41: 1113-1117, 2018. doi: 10.1097/COC.0000000000000438
TORG1016 Ikeda S, Kato T, Ogura T, et al.: Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016. BMC Cancer 18: 241, 2018

2017年 発表論文

研究No. 執筆者/論文タイトル/掲載誌
TORG0604 Misumi Y, Okamoto H, Sasaki J, et al.: Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604. BMC Cancer 17: 377, 2017

2016年 発表論文

研究No. 執筆者/論文タイトル/掲載誌
TORG0912 Takayama K, Atagi S, Imamura F, et al.: Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients?Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study. Support Care Cancer 24 (8): 3473-3480, 2016
TORG1015 Kozuki T, Nogami N, Kitajima H, et al.: Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent nonsquamous non- small cell lung cancer in elderly patients: TORG1015. BMC Cancer 16: 306, 2016

2015年 発表論文

研究No. 執筆者/論文タイトル/掲載誌
TORG0910 Yamada K, Saito H, Kondo T, et al.: Multicenter phase II study of nedaplatin and irinotecan for patients with squamous cell carcinoma of the lung: Thoracic Oncology Research Group 0910. Anticancer Research 35 (12): 6705-6711, 2015
TORG0911 Yamada K, Aono H, Hosomi Y, et al.: A prospective, multicenter phase II trial of low-dose erlotinib monotherapy for patients with previously treated non?small cell lung cancer with EGFR mutations: Thoracic Oncology Research Group 0911. European Journal of Cancer 51 (14) : 1904-1910, 2015
TORG1014 Takagi Y, Hosomi Y, Oshita F, et al.: Feasibility study of docetaxel plus bevacizumab therapy for elderly patients with non-small cell lung cancer: Thoracic Oncology Research Group (TORG) 1014. BMC Cancer 15: 740, 2015

2014年 発表論文

研究No. 執筆者/論文タイトル/掲載誌
TORG1016 Ikeda S, Sekine A, Kato T, et al.: Diffuse alveolar hemorrhage as a fatal adverse effect of bevacizumab: an autopsy case. Japanese Journal of Clinical Oncology 44 (5) : 497-500, 2014

2013年 発表論文

研究No. 執筆者/論文タイトル/掲載誌
TORG0809 Niho S, Ikeda N, Michimae H, et al.: Feasibility trial for adjuvant chemotherapy with docetaxel plus cisplatin followed by single agent long-term administration of S-1 chemotherapy in patients with completely resected non-small cell lung cancer: Thoracic Oncology Research Group Study 0809. British Journal of Cancer 109 (3) : 545-551, 2013

2011年 発表論文

研究No. 執筆者/論文タイトル/掲載誌
TORG0705 Takiguchi Y, Seto T, Ichinose Y, et al.: Long-Term Administration of Second-Line Chemotherapy with S-1 and Gemcitabine for Platinum-Resistant Non-small Cell Lung Cancer A Phase II Study. Journal of Thoracic Oncology 6 (1) : 156-160, 2011

2010年 発表論文

研究No. 執筆者/論文タイトル/掲載誌
TORG0502 Seto T, Yamanaka T, Wasada I, et al.: Phase I/II trial of gemcitabine plus oral TS-1 in elderly patients with advanced non-small cell lung cancer: Thoracic oncology research group study 0502. Lung Cancer 69 (2) : 213-217, 2010

2006年 発表論文

研究No. 執筆者/論文タイトル/掲載誌
TORG0301 Onoda S, Masuda N, Seto T, et al.: Phase II Trial of Amrubicin for Treatment of Refractory or Relapsed Small-Cell Lung Cancer: Thoracic Oncology Research Group Study 0301. Journal of Clinical Oncology 24 (34) : 5448-5453, 2006


ページトップへ